Perrigo Company plc (PRGO)
After hours:
| Previous close | 31.27 |
| Open | 31.23 |
| Bid | 31.97 x 800 |
| Ask | 32.11 x 800 |
| Day's range | 31.13 - 32.29 |
| 52-week range | 25.77 - 40.28 |
| Volume | |
| Avg. volume | 1,999,253 |
| Market cap | 4.328B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.10 (3.50%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
- PR Newswire
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that pharmaceutical company Esteve Healthcare, S.L. ("ESTEVE") has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones.
- PR Newswire
Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial results on Tuesday, May 7th, 2024, and host a conference call beginning at 8:30 A.M. (EDT).
- PR Newswire
Opill and WNBA Team Up for Groundbreaking Partnership
Today, Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that Opill® — the first-ever daily birth control pill available without a prescription in the U.S. — and the Women's National Basketball Association (WNBA) have entered a multi-year partnership that focuses on building confidence, strength and health equity, all of which closely align with both organizations' core priorities.
